APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE

Martínez Casanova N1, Sánchez Yañez E1, Gómez Delgado M1, 2Hospital Virgen de la Victoria Málaga Spain
Contact: nuria.martinez.casanova.sspa@juntadeandalucia.es

AIM
Describe the prescription of ustekinumab in real-life condition in our hospital

BACKGROUND
Anti-TNF are recognised as the primary therapeutic option for patient with moderate to severe Crohn

OBJECTIVES
To assess the appropriateness of ustekinumab prescription.

POPULATION
All patients treated with ustekinumab were included 2017-2021

APPROPRIATENESS PRESCRIPTION
- Therapeutic drug monitoring
- Intensification before switching
- Contraindications to use anti-TNF

VARIABLES
- Demographic
- Previous anti-TNFα agents used
- Dose or Interval intensification
- Drug trough
- Anti-drug antibodies measurements
- Primary or secondary failure
- Concomitant medication
- Ustekinumab dose
- Reason to switch (biomarkers, symptoms, mucosal inflammation

MATERIAL AND METHODS

RESULTS

THE 56.1% OF THE PRESCRIPTION WERE CONSIDERED INAPPROPRIATE

47 patients Average age: 46,5
Median dose ustekinumab 387,8 mg

CONCLUSION AND RELEVANCE

Given the high number of patients without therapeutic drug monitoring or without dose or interval intensification, it was decided to create: an interdisciplinary comission made up of digestive and pharmaceutical in order to optimize the drug prescription in Crohn’s disease

REFERENCES:
[1] Link to References